The 'death pace' in the CO.17 trial.
In an era where the cost of care in oncology is rising, suggestions of new frameworks that may help in orienting biomarker discovery are highly desirable. We propose a different perspective for looking at survival data, which we call 'death pace' analysis, which focuses on the variation of the gap between survival curves over time and that may make it easier to identify subpopulations with distinct predictive molecular features. The recently published data on EJC on the impact of the primary colonic site in the CO.17 trial seem to be particularly suitable for the death pace analysis.